Stauffer, John L.

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K.-U., & Costabel, U. (2017) · European Respiratory Review

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 295

Morphology of the Uvula in Obstructive Sleep Apnea

Stauffer, J. L., Buick, M. K., Bixler, E. O., Sharkey, F. E., Abt, A. B., Manders, E. K., Kales, A., Cadieux, R. J., Barry, J. D., & Zwillich, C. W. (1989) · American Review of Respiratory Disease

Obstructive Sleep Apnea ResearchOropharyngeal Anatomy and Pathologies

Cited by 185

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis

Flaherty, K. R., Fell, C. D., Huggins, J. T., Nunes, H., Sussman, R., Valenzuela, C., Petzinger, U., Stauffer, J. L., Gilberg, F., Bengus, M., et al. (2018) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 141

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study

Cottin, V., Koschel, D., Günther, A., Albera, C., Azuma, A., Sköld, C. M., Tomassetti, S., Hormel, P., Stauffer, J. L., Strombom, I., et al. (2018) · ERJ Open Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPharmacovigilance and Adverse Drug Reactions

Cited by 121